This article has been reviewed according to Science X's editorial process and policies. Editors have highlighted the following attributes while ensuring the content's credibility:


peer-reviewed publication

trusted source


Novel radiotracer rapidly detects gastrointestinal cancer biomarker, identifies patients for targeted therapy

Novel radiotracer rapidly detects gastrointestinal cancer biomarker, identifies patients for targeted therapy
(A) Patient 9 was woman with advanced gastric cancer whose CLDN18.2 expression level was 40%, 2+. Left pleural metastatic nodule (blue arrow) and thickened peritoneum (white arrow) did not show obvious uptake on 18F-FDG PET/CT, whereas 68Ga-NC-BCH PET/CT showed high uptake (SUVmax, 3.1 [red arrow] and 5.7 [green arrow]). (B) Patient 4 was man with colon cancer whose CLDN18.2 expression level was 40%, 3+. On 18F-FDG PET/CT, abdominal metastatic lymph node (white arrow) showed mild uptake, whereas same lymph nodes on 68Ga-NC-BCH PET/CT (blue arrow) showed high uptake (SUVmax, 1.4 vs. 5.6). Credit: Journal of Nuclear Medicine (2024). DOI: 10.2967/jnumed.123.267110

A new PET radiotracer enables same-day imaging of the important gastrointestinal cancer biomarker known as Claudin18.2 (CLDN18.2). Uptake of the radiotracer, 68Ga-NC-BCH, was found to correlate significantly with CLDN18.2 expression, a promising finding that could allow oncologists to optimize treatment for patients and monitor their response.

The research was published in the June issue of the Journal of Nuclear Medicine.

Gastrointestinal cancers are one of the most common types of cancer across the globe, accounting for more than a quarter of the total cancer incidence and more than one-third of cancer-related deaths each year. Early symptoms can be deceptive, and most gastrointestinal cancers are diagnosed at an often leading to a and increased mortality.

The protein CLDN18.2 is highly expressed in and several forms of CDLN18.2-targeted therapies are currently undergoing clinical trials. There is no standard test for CLDN18.2, however, and most involve immunohistochemistry, an invasive process that covers only a small amount of tissue and does not reflect the heterogeneity of CLDN18.2 expression in tumors.

"The detection of CLDN18.2 is essential for identifying patients who can benefit from targeted therapies," said Hua Zhu, Ph.D., professor at Peking University Cancer Hospital in Beijing, China. "In this study, we developed a CLDN18.2-targeting radiotracer and conducted whole-body PET imaging to determine its ability to detect the biomarker."

Researchers first synthesized the radiotracer 68Ga-NC-BCH and performed preclinical evaluations on human gastrointestinal cancer cell lines and mouse models. Next, 11 patients underwent whole-body 68Ga-NC-BCH PET and 18F-FDG PET, and radiopharmaceutical biodistribution, radiation dosimetry, and the relationship between uptake and CLDN18.2 were evaluated.

68Ga-NC-BCH was stably prepared and demonstrated good radiochemical properties. The radiotracer exhibited rapid blood clearance, for CLDN18.2, and high specific uptake in CLDN18.2-positive cells and xenograft mouse models.

In patients, 68Ga-NC-BCH displayed high uptake in the stomach and kidney and slight uptake in the pancreas. Compared with 18F-FDG, 68Ga-NC-BCH identified more lesions in the and peritoneum, the most common metastatic sites of advanced gastric cancer.

"68Ga-NC-BCH PET is a safe, noninvasive imaging method for detecting CLDN18.2 expression in patients," said Zhu. "The rapid uptake of the radiotracer allows patients to complete the whole imaging workflow within one day, greatly increasing compliance and reducing radiation exposure. This can greatly help oncologists in making treatment decisions."

More information: Changsong Qi et al, 68Ga-NC-BCH Whole-Body PET Imaging Rapidly Targets Claudin18.2 in Lesions in Gastrointestinal Cancer Patients, Journal of Nuclear Medicine (2024). DOI: 10.2967/jnumed.123.267110

Journal information: Journal of Nuclear Medicine
Citation: Novel radiotracer rapidly detects gastrointestinal cancer biomarker, identifies patients for targeted therapy (2024, June 6) retrieved 24 July 2024 from
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.

Explore further

Novel PET radiotracer successfully detects multiple cancers, offers potential for new targeted radionuclide therapy


Feedback to editors